Yin Liang

US Patent:

20040005299, Jan 8, 2004

Filed:

Mar 21, 2003

Appl. No.:

10/394902

Inventors:

Yin Liang - Bridgewater NJ, US
Jian Zhu - North Haven CT, US
Laurel Sweet - Branford CT, US
James Livingston - Guilford CT, US

Assignee:

Bayer Pharmaceuticals Corporation - West Haven CT

International Classification:

A61K045/00
C12N005/08

US Classification:

424/093700, 435/366000

Abstract:

The present invention relates to a method for preparing pseudo islets. In addition, the invention is also directed to methods of treating diabetes and diabetes-related disorders by administering compounds identified by the methods described herein.

US Patent:

20070219245, Sep 20, 2007

Filed:

Mar 13, 2007

Appl. No.:

11/685247

Inventors:

Cuifen Hou - Spring House PA, US
Yin Liang - Ambler PA, US
Keith T. Demarest - Flemington NJ, US
Druie E. Cavender - Flemington NJ, US
Michael P. Wachter - Bloomsbury NJ, US
Mingde Xia - Belle Mead NJ, US

International Classification:

A61K 31/4545

US Classification:

514316

Abstract:

The present invention is directed to a method for use of substituted dipiperidine compounds of Formula (I)or a salt, isomer, prodrug, metabolite or polymorph thereof, which are CCR2 antagonists, for preventing, treating or ameliorating syndromes, disorders or diseases related to CCR2 activation in a subject in need thereof.

US Patent:

20110009347, Jan 13, 2011

Filed:

Jul 6, 2010

Appl. No.:

12/830479

Inventors:

Yin Liang - Ambler PA, US
John Ryan - Chalfont PA, US
Abraham B. Woldu - Souderton PA, US
Lisa Wu - Merion Station PA, US

International Classification:

A61K 31/7064
A61K 31/7042
A61P 3/10
A61P 43/00
A61P 5/50
A61P 3/00
A61P 3/06
A61P 3/04
A61P 9/10
A61P 9/12

US Classification:

514 23

Abstract:

The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein.

US Patent:

20110065200, Mar 17, 2011

Filed:

Sep 14, 2010

Appl. No.:

12/881695

Inventors:

Keith T. Demarest - Flemington NJ, US
James M. Lenhard - Fort Washington PA, US
Gregory C. Leo - Lansdale PA, US
Yin Liang - Owings Mills MD, US
Tonya L. Martin - Quakertown PA, US

Assignee:

Janssen Pharmaceutica, N.V. - Beerse

International Classification:

G01N 33/50

US Classification:

436 93

Abstract:

Presented here are methods using alpha-methylglucoside (AMG) in vivo as an indicator for glucose absorption from the gastrointestinal (GI) system or glucose excretion in the urine after oral administration of AMG. The methods find use in, for example, but not limited to, determining the effect of a sodium-dependent glucose transporter (SGLT) inhibitor in an animal, comparing the differences in the effects of a first and second SGLT inhibitor in an animal, and diagnosing a disease associated with glucose absorption from the gastrointestinal (GI) system or glucose excretion from the kidney in an animal.

US Patent:

20190367469, Dec 5, 2019

Filed:

Nov 8, 2017

Appl. No.:

16/348304

Inventors:

- Beerse, BE
Guozhang Xu - Chesterbrook PA, US
Yin Liang - Ambler PA, US

Assignee:

Janssen Pharmaceutica NV - Beerse

International Classification:

C07D 309/10

Abstract:

The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.